Related Experiment Video
Updated: Jun 17, 2025
10:42
A Free-breathing fMRI Method to Study Human Olfactory Function
Published on: July 30, 2017
9.6K
The current status and challenges of olfactory dysfunction study in Alzheimer's Disease
Wanchen Liao1, Yulin Wang1, Lei Wang1
1Department of Alzheimer's Disease Clinical Research Center, Guangdong Second Provincial General Hospital, Guangzhou 510317, China.
Ageing Research Reviews
|August 10, 2024
Summary
Olfactory dysfunction, a symptom of Alzheimer's Disease (AD), can be detected early using smell tests. These tests, combined with other biomarkers, show promise for diagnosing AD before mild cognitive impairment (MCI).
Area of Science:
- Neuroscience
- Medical Diagnostics
- Cognitive Science
Background:
- Olfactory functioning integrates complex cognitive processes and neural systems.
- Disruptions in olfaction lead to olfactory dysfunction, a potential early indicator for diseases like Alzheimer's Disease (AD).
- Brain imaging and electroencephalography (EEG) reveal changes in olfactory areas of AD patients.
Purpose of the Study:
- To explore the potential of olfactory dysfunction in the preclinical detection of Alzheimer's Disease (AD).
- To evaluate the utility of olfactory tests for early AD diagnosis, preceding mild cognitive impairment (MCI).
Main Methods:
- Utilizing medical imaging and electroencephalography (EEG) to observe changes in olfactory brain regions.
- Applying olfactory tests for screening in community cohorts due to their high specificity.
- Investigating the combination of olfactory tests with other biomarkers for enhanced AD prediction.
Main Results:
- Olfactory dysfunction is a significant indicator for detecting AD during its preclinical stage.
- Olfactory tests demonstrate high specificity for screening AD in general populations.
- Combining olfactory tests with additional biomarkers may improve early AD diagnosis accuracy.
Conclusions:
- Olfactory dysfunction is a promising biomarker for the early detection of Alzheimer's Disease (AD).
- Specific olfactory tests are valuable tools for preclinical AD screening.
- Integrated diagnostic models combining olfactory assessments and other biomarkers can enhance early AD diagnosis sensitivity and specificity.
Related Concept Videos
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171